TrueTicker

NIFTY 500 › Chemicals

Chemicals · NIFTY 500

Jubilant Ingrevia Ltd.

JUBLINGREA on NSE · 19 Nov 2026

NIFTY 500

573.70 ▼ -2.24 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Filings

49 filings of JUBLINGREA since January 2025; the newest 40 below.

presentation 19, board outcome 12, transcript 9, dividend 5, results 2, credit rating 2

FiledTypeSubject
02 Nov 2026transcript
Acquisition, Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q2 and H1 FY27 investors' conference call held on October 27, 2026, for results ended September 30, 2026.

Management (Shyam Bhartia, Chairman) said Q2 revenue grew 24% year-on-year to INR1,394 crore, EBITDA rose 51% to INR221 crore and PAT rose 60% to INR111 crore.

Management said the company signed an agreement to acquire a 40% stake in Zettaone Technologies Limited for INR189 crore, and expects Zettaone's business to grow at least 60% to 70% this year.

Management (Deepak Jain, CEO and MD) said the company is sticking to its annual guidance of INR750-800 crore and expects to be closer to the upper end, and that a large CDMO contract's future volume visibility is expected within weeks.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026presentation
Acquisition, Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Press Release and Presentation on the financials and operational performance of the Company for the quarter and half year ended Se
AI summary

Jubilant Ingrevia filed its Q2 FY27 press release and investor presentation for the quarter and half year ended September 30, 2026.

Q2 FY27 total revenue was Rs 1,394 crore (up 24% YoY); EBITDA was Rs 221 crore (up 51% YoY) at a 16% margin; PAT was Rs 111 crore (up 61% YoY).

H1 FY27 total revenue was Rs 2,695 crore (up 25% YoY); EBITDA was Rs 431 crore (up 44% YoY); PAT was Rs 217 crore (up 50% YoY).

The company said it has signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited for Rs 189.2 crore, which management said will give it entry into the EDMS space.

Management said it expects growth across all three business segments in FY27 and that the new Multi-Purpose Plant remains on track for commissioning by year-end.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026presentation
Acquisition, Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Investor Presentation
AI summary

Jubilant Ingrevia reported Q2 FY27 (quarter ended September 30, 2026) total revenue of Rs 1,394 crore, up 24% YoY, and EBITDA of Rs 221 crore, up 51% YoY, with EBITDA margin of 16%.

PAT after exceptional items was Rs 111 crore, up 61% YoY; basic EPS was Rs 7.1.

For H1 FY27, revenue rose 25% to Rs 2,695 crore and EBITDA rose 44% to Rs 431 crore; PAT rose 50% to Rs 217 crore.

Management (Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia) said the company signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited for Rs 189.2 crore, entering the EDMS space.

CEO Deepak Jain said management expects growth across all three segments in FY27, particularly Acetyls, and that the new Multi-Purpose Plant remains on track for commissioning by year-end.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026board outcome
Results
Outcome of the Board Meeting held on October 27, 2026
AI summary

Outcome of the board meeting held on October 27, 2026 (11:10 a.m. to 2:00 p.m.), filed under Regulation 33 read with Regulation 30 of the Listing Regulations.

The board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

The limited review report from the statutory auditors on the unaudited results is enclosed.

The results documents are also available on the company's website, www.jubilantingrevia.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Oct 2026board outcome
Capex, Dividend / buy-back
Jubilant Ingrevia Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.
AI summary

Jubilant Ingrevia's board approved, on the recommendation of the Nomination, Remuneration and Compensation Committee, an amendment to the Jubilant Ingrevia Employee Stock Option Plan 2021 (ESOP Plan) on October 01, 2026, subject to shareholder approval.

The amendment increases the ESOP pool from 20,00,000 to 30,00,000 stock options, exercisable into equivalent equity shares.

The 30,00,000 options would convert into 30,00,000 equity shares, equal to 1.88% of paid-up share capital as on September 30, 2026.

The company said the existing pool may not be adequate for its talent retention, leadership succession and strategic hiring needs.

The event occurred at 07:25 PM (IST) on October 01, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Oct 2026board outcome
Acquisition, Capex
Jubilant Ingrevia Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026 for incorporation of a wholly owned subsidiary
AI summary

Jubilant Ingrevia Limited filed a Regulation 30 disclosure dated October 1, 2026, following its August 18, 2026 disclosure on a Binding Term Sheet with Zettaone Technologies India Private Limited for a 40% strategic equity stake.

The Board, at its meeting held on October 1, 2026, approved incorporation of a wholly owned subsidiary, Jubilant Advanced Electronics Limited, through which the 40% Zettaone stake will be acquired instead of directly by the Company.

The proposed subsidiary will be registered in Gurugram, Haryana, and is to manufacture electronic products and semiconductors; incorporation is under process.

The Company will subscribe 100% of the initial paid-up share capital in cash, up to Rs.10,00,00,000 (1,00,00,000 equity shares of Rs 10 each at par).

Management said the structure is intended to provide operational flexibility and strategic focus in the EDMS and electronics and semiconductor segments, in furtherance of its Pinnacle Growth Strategy.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Jul 2026transcript
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q1 FY27 investors' conference call, held July 23, 2026, on its results for the quarter ended June 30, 2026.

Management (Chairman Shyam Bhartia) said revenue grew 25% year-on-year and EBITDA rose 36% year-on-year, and expects sequential improvement in revenue and EBITDA over the coming quarters.

CEO Deepak Jain reported Q1 revenue of INR1,300 crore, EBITDA of INR209 crore and PAT of INR106 crore, up 41% year-on-year.

Management said the Chemical Intermediates segment revenue rose to INR524 crore and Nutrition segment revenue to INR243 crore, and that the new multipurpose plant remains on track for commissioning by end of the calendar year.

On a CDMO contract with an innovator, Jain said the company maintains its earlier EBITDA expectations and has full protection in case volumes are not given.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 Jul 2026presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Investor Presentation
AI summary

Jubilant Ingrevia filed its press release and presentation on Q1 FY27 (quarter ended June 30, 2026) results, to be discussed on an investor conference call on July 23, 2026.

Total revenue for Q1 FY27 was Rs 1,300 crore, up 25% YoY and 10% QoQ; EBITDA was Rs 209 crore, up 36% YoY; PAT was Rs 106 crore, up 41% YoY; basic EPS was Rs 6.7.

Management (Deepak Jain, CEO and MD) said the quarter was a strong start to the year, citing healthy volume growth, improved realizations and cost pass-through despite Middle East supply chain disruptions.

Management said it expects growth in FY2027 to be led by Specialty Chemicals and Nutrition, with a recovery in Acetyls, and anticipates sequential improvement in revenue and EBITDA over coming quarters.

The new Multi-Purpose Plant is on track for commissioning by the end of the current calendar year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 Jul 2026presentation
Acquisition, Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated July 22, 2026, titled "Press Release and presentation on the financials and operational performance of the Company for the quarter ended June 30, 2026".
AI summary

Jubilant Ingrevia filed the press release and presentation on its results for the quarter ended June 30, 2026 (Q1'FY27), with the earnings call scheduled for July 23, 2026.

Q1'FY27 total revenue was Rs 1,300 crore, up 25% YoY and 10% QoQ; EBITDA was Rs 209 crore (16% margin), up 36% YoY; PAT was Rs 106 crore, up 41% YoY; basic EPS was Rs 6.7.

Management (Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia) said the company is "confident of continuing our growth momentum" and expects FY2027 growth led by Specialty Chemicals and Nutrition, with a recovery in Acetyls and sequential improvement in revenue and EBITDA over coming quarters.

Management (CEO and MD Deepak Jain) said the new Multi-Purpose Plant remains on track for commissioning by the end of the current calendar year, and that the Remidex Pharma integration is complete.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 Jul 2026board outcome
Results
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Jubilant Ingrevia Limited filed the outcome of its board meeting held on July 22, 2026, which ran from 11:00 a.m. to 12:25 p.m.

The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

The filing encloses the results and the Limited Review Report from the statutory auditor, Walker Chandiok & Co LLP, which carries no modification of opinion.

The auditor notes that a subsidiary's figures (total revenue of Rs 659 lakhs, net profit after tax of Rs 33 lakhs) were reviewed by another auditor, and that an associate's share of net loss of Rs 3 lakhs was not reviewed by its auditor.

The filing gives no revenue or profit figures for the group as a whole.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q4 and FY26 investor earnings call held on May 26, 2026, referring to audited standalone and consolidated results for the quarter and year ended March 31, 2026.

Management (Chairman Shyam Bhartia, CEO and MD Deepak Jain) said Q4 FY26 revenue of Rs. 1,179 crore was the highest in 14 quarters, up 12% year-on-year, with EBITDA of Rs. 172 crore (up 11% year-on-year) and PAT of Rs. 86 crore (up 17% year-on-year).

Management said the Board recommended a final dividend of Rs. 2.5 per share, taking the FY26 total to Rs. 5 per share, with a total cash outflow of Rs. 79.8 crore.

Management expects FY27 growth led by Specialty Chemicals and Nutrition, expects sequential revenue and EBITDA growth from Q1 FY27, and aspires to at least 20% year-on-year full-year EBITDA growth but does not give quarterly growth guidance.

Management said net debt to EBITDA improved to 0.99x and that the Remidex Pharma acquisition was completed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026presentation
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Investor Presentation
AI summary

Jubilant Ingrevia reported Q4 FY26 revenue of ₹1,179 crore (up 12% YoY) and EBITDA of ₹172 crore (up 11% YoY); PAT was ₹86 crore (up 17% YoY). FY26 revenue was ₹4,388 crore (up 5%), EBITDA ₹607 crore (up 9%) and PAT ₹278 crore (up 11%).

The Board recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per share (500%).

Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said the company handled the Middle East crisis with no force majeure and zero production loss, and expect sequential revenue and EBITDA growth starting Q1 FY27.

CEO and Managing Director Deepak Jain said net debt/EBITDA improved to 0.99x and the Gajraula Multi Purpose Plant construction is progressing well; Q4 capex cash outflow was ₹69 crore.

The company completed the acquisition of Remidex Pharma to expand its human nutrition premixes business.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026presentation
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Press release and presentation on the financials and operational performance of the Company for the Quarter and Financial Year ended M
AI summary

Jubilant Ingrevia reported Q4 FY26 revenue of ₹1,179 crore (up 12% YoY), EBITDA of ₹172 crore (up 11% YoY) and PAT of ₹86 crore (up 17% YoY); FY26 revenue was ₹4,388 crore (up 5%) and PAT ₹278 crore (up 11%).

The Board recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per share (500%).

Management (Chairman and Co-Chairman) said the company handled the Middle East crisis with no force majeure and zero production loss, and expects sequential growth in revenue and EBITDA starting Q1 FY27.

Management (CEO and MD Deepak Jain) said Specialty Chemicals and Nutrition are expected to lead FY27 growth, with recovery in Acetyls, and that the Gajraula Multi Purpose Plant construction is progressing well.

The company completed the acquisition of Remidex Pharma to strengthen its Human Nutrition premixes portfolio; Q4 capex outflow was ₹69 crore, mainly for the Bharuch CDMO plant commissioning and Gajraula groundbreaking.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026board outcome
Dividend / buy-back, Legal
Jubilant Ingrevia Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2026.
AI summary

Board meeting held May 26, 2026 (11:10 a.m. to 2:30 p.m.) recommended a final dividend of 250% i.e. Rs. 2.50 per equity share of Re. 1 each for FY ended March 31, 2026, subject to shareholder approval at the AGM.

Dividend to be paid/dispatched within 30 days from the AGM date.

Friday, July 24, 2026 fixed as the record date for the final dividend payment.

Board approved re-appointment of M/s J.K. Kabra & Co. (Cost Accountants) as Cost Auditors for FY 2026-27, with details in Annexure-A.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026dividend
Dividend / buy-back
Jubilant Ingrevia Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 2.5 per equity share.
AI summary

Jubilant Ingrevia Limited filed the outcome of its board meeting held on May 26, 2026.

The board recommended a final dividend of Rs. 2.50 per equity share (250% of face value of Re. 1) for FY ended March 31, 2026, payable within 30 days of the AGM if approved by shareholders.

July 24, 2026 was fixed as the record date for the final dividend.

The board re-appointed J.K. Kabra & Co. as Cost Auditors for FY 2026-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026board outcome
Results
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Outcome of the Board Meeting held on May 26, 2026 (11:10 a.m. to 2:30 p.m.): the Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

The Board took on record the auditor's reports with unmodified opinion on the audited financial results.

The filing encloses the audited results, the auditor's reports and a CFO declaration confirming the unmodified opinion.

The filing does not state revenue, profit, dividend or other figures in the text provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Feb 2026transcript
Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q3 and 9M FY26 earnings conference call held February 05, 2026, covering results for the quarter ended December 31, 2025.

Management said Q3 revenue was INR1,051 crore versus INR1,057 crore a year earlier, with volumes up nearly 9%, while EBITDA was INR136 crore, down 8% year on year due to lower pricing.

Management said 9-month EBITDA rose 8% to INR436 crore, and PAT for the quarter after exceptional items was INR47 crore versus INR69 crore a year earlier; the exceptional item of INR13 crore relates to the Indian Labour Code amendments.

The Board recommended an interim dividend of 250%, equal to INR2.5 per equity share.

Management said year-to-date capex was INR366 crore and planned capex is about INR500 crore in 2027, funded by internal accruals; net debt-to-EBITDA improved to 0.94x from 1.24x.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026presentation
Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding 'Presentation on the financials and operational performance of the Company for the quarter ended December 31, 2025'.
AI summary

Jubilant Ingrevia filed its press release and investor presentation for the quarter ended December 31, 2025 (Q3 FY26), ahead of an investor call on February 5, 2026.

Q3 FY26 total revenue was Rs 1,051 crore (down 1% YoY, down 6% QoQ); EBITDA was Rs 136 crore with a 13% margin; PAT after exceptional items was Rs 47 crore (down 32% YoY).

For nine months FY26, total revenue rose 3% to Rs 3,210 crore, EBITDA rose 8% to Rs 436 crore and PAT rose 8% to Rs 191 crore, after a one-time exceptional expense linked to the amendment to the Indian Labour Code.

The Board recommended an interim dividend of 250%, i.e. Rs 2.5 per equity share.

Management said pricing pressure persisted across segments in the quarter, partly offset by strong volume growth, and expects sustained growth momentum in Q4 FY26, with a major CDMO order delivery and the $300 million Agro-Innovator project commissioning slated for Q4.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026presentation
Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Press Release and presentation on the financials and operational performance ofthe Company for the quarter ended December 31, 202
AI summary

Jubilant Ingrevia filed its press release and investor presentation for the quarter ended December 31, 2025 (Q3 FY26), to be discussed on an investor call on February 5, 2026.

Q3 FY26 total revenue was Rs 1,051 crore (down 1% YoY, 6% QoQ); EBITDA was Rs 136 crore with a 13% margin; PAT after exceptional items was Rs 47 crore versus Rs 69 crore in Q3 FY25.

9M FY26 total revenue was Rs 3,210 crore (up 3% YoY), EBITDA Rs 436 crore (up 8%) and PAT Rs 191 crore (up 8%), after an exceptional expense linked to the amendment to the Indian Labour Code.

The Board recommended an interim dividend of 250%, equal to Rs 2.5 per equity share.

Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said management expects sustained growth momentum in Q4 FY26, with a major CDMO order delivery starting in Q4 and the Rs 300 crore... Agro-Innovator project slated to begin dispatches from March 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2026dividend
Dividend / buy-back, Management change
Jubilant Ingrevia Limited has informed the Exchange that Board of Directors at its meeting held on February 04, 2026, declared Interim Dividend of 2.50 per equity share.
AI summary

Jubilant Ingrevia Limited filed the outcome of its board meeting held on February 4, 2026.

The board declared an interim dividend of Rs.2.50 per equity share of Re. 1 each for FY 2025-26.

February 10, 2026 is fixed as the record date for the interim dividend, which will be paid on or before March 4, 2026.

The board approved re-appointment of Ms. Ameeta Chatterjee (DIN: 03010772) as an Independent Director for five years from April 17, 2026 to April 16, 2031, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2026dividend
Dividend / buy-back, Management change
Jubilant Ingrevia Limited has informed the Exchange that Board of Directors at its meeting held on February 04, 2026, declared Interim Dividend of Rs. 2.50 per equity share.
AI summary

Jubilant Ingrevia Limited filed the outcome of its board meeting held on February 4, 2026.

The board declared an interim dividend of Rs. 2.50 per equity share of Re. 1 each for FY 2025-26.

February 10, 2026 is fixed as the record date for the interim dividend, which will be paid on or before March 4, 2026.

The board approved re-appointment of Ms. Ameeta Chatterjee as an Independent Director for five years from April 17, 2026 to April 16, 2031, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2026board outcome
Results
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Jubilant Ingrevia Limited filed the outcome of its board meeting held on February 04, 2026 (2:00 p.m. to 5:15 p.m.), which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

The filing encloses the unaudited standalone and consolidated results and the limited review reports from Walker Chandiok & Co LLP on the consolidated results, dated February 04, 2026.

The auditor's review reported no material misstatement, and its conclusion relies on another auditor's review of one associate, whose share of net loss was Rs 2 lakhs for the quarter and Rs 16 lakhs for the year to date.

The results are also available on the company's website.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Dec 2025credit rating
Rating
Jubilant Ingrevia Limited has informed the Exchange about Credit Rating- Revision
AI summary

India Ratings and Research published a rating on the company's debt instruments on December 02, 2025.

Bank loan facilities of Rs. 23,883.8 million (reduced from Rs. 24,200 million) rated IND AA+/Stable/IND A1+, affirmed.

Proposed commercial paper of Rs. 4,000 million: rating withdrawn (WD).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Nov 2025presentation
Capex, Guidance, Management change, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Jubilant Ingrevia intimated participation in the Kotak Midcap Conference 2025 (revised event name from 'Midcap Conference 2025'), in person at Grand Hyatt, BKC Mumbai on Friday, November 21, 2025, 10:00 am to 5:00 pm, with group and one-on-one meetings; a presentation will be used.

The filing encloses an investor presentation covering Q2 FY26 results. Management said Specialty Chemicals grew double digits year-on-year with 25%+ margins, EBITDA grew 8% year-on-year and Profit After Tax rose 18% in the quarter.

Management said half-yearly EBITDA grew 18% and Profit After Tax rose 34%, and expects continued growth momentum in H2 FY26 with a major CDMO order to start in early 2026.

Management said a new MPP in Gajraula had its ground-breaking and is expected to be completed by late 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Nov 2025presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Jubilant Ingrevia intimated that its management will participate in the Midcap Conference 2025 at Grand Hyatt, BKC Mumbai on November 21, 2025 (10:00 am to 5:00 pm), in person, with group and one-on-one meetings.

The enclosed investor presentation (November 2025) covers Q2 FY26 highlights and business segment updates.

Chairman Shyam S Bhartia said EBITDA grew 8% year-over-year and Profit After Tax rose 18% in the quarter; on a half-yearly basis EBITDA grew 18% and PAT surged 34%.

Management said Specialty Chemicals reported 25%+ margins and that 10+ new CDMO/Fine Chemicals molecules are expected to contribute Rs 1200 crore+ of peak annual revenue in coming years.

Management expects continued growth momentum in H2 FY26, a part-recovery in Acetyls, and the start of a major CDMO order in early 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Nov 2025presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Jubilant Ingrevia intimated that management will attend investor/analyst conferences: Anand Rathi Institutional Equities G200 Summit, Taj Santacruz, Mumbai, on November 13, 2025 (11:00am to 7:00pm, in-person, group and one-on-one meetings, presentation included) and a second event on November 14, 2025 (10:00am to 5:00pm).

The company filed its investor presentation for November 2025, which includes Q2 FY26 highlights.

Chairman Shyam S Bhartia said Specialty Chemicals revenue grew double digits year-on-year, EBITDA rose 8% year-on-year and profit after tax rose 18% in the quarter, with half-yearly EBITDA up 18% and PAT up 34%.

Management said CDMO/Fine Chemicals volumes were strong, 10+ new molecules were added in recent quarters with expected peak annual revenue of 1200cr+, and the major CDMO order is on track to start in early 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Nov 2025presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Jubilant Ingrevia intimated that its management will attend investor/analyst conferences: Anand Rathi Institutional Equities G200 Summit on November 13, 2025 (11:00 am to 7:00 pm, Taj, Santacruz, Mumbai, in-person, group and one-on-one meetings) and a second event on November 14, 2025 (10:00 am to 5:00 pm).

The company attached its November 2025 investor presentation covering Q2 FY26 highlights.

Management (Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia) said Q2 EBITDA grew 8% year-over-year and Profit After Tax rose 18%; on a half-yearly basis EBITDA grew 18% and PAT rose 34%.

Management said it expects continued growth momentum in H2 FY26 and that its major CDMO order is on track to start in early 2026; a new MPP at Gajraula is under construction, targeted for completion by late 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025transcript
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q2 and H1 FY26 earnings conference call held October 27, 2025, for quarter and half year ended September 30, 2025.

Shyam Bhartia (Chairman) said quarterly revenue grew 7% year-on-year with high double-digit volume growth, EBITDA rose 8% and profit after tax rose 18%; for H1, EBITDA rose 18% and profit after tax rose 34%.

Deepak Jain (CEO and MD) said revenue of INR1,121 crore was the highest in the last 10 quarters, versus INR1,045 crore in Q2 FY25, and the company expects the Q4 FY26 commissioning of its $300 million Agro-Innovator project.

Varun Gupta (CFO) said volume grew about 18% in the quarter, quarterly EBITDA was INR146 crore and H1 EBITDA was INR300 crore.

Management said it expects continued growth momentum in H2 FY26 and remains confident in sustaining growth in top line and margins over coming quarters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2025board outcome
Capex
Jubilant Ingrevia Limited has informed the Exchange regarding Outcome of Board Meeting held on October 27, 2025.
AI summary

Board of Jubilant Ingrevia Limited, at its meeting held on October 27, 2025 (1:30 p.m. to 3:50 p.m.), approved the grant of 1,23,704 stock options/RSUs to eligible employees under the Jubilant Ingrevia Employees Stock Option Plan 2021.

The grant covers 1,23,704 equity shares of face value Re. 1 each: 47,694 RSUs with an exercise price of Re. 1 each, and 76,010 stock options with an exercise price of Rs. 677.70 each.

Stock options vest 20% at end of 1st year, 30% at end of 2nd year and 50% at end of 3rd year; RSUs vest at end of 3rd year.

Stock options are exercisable within 8 years from grant; RSUs are exercisable within 1 year from vesting.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2025presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated October 27, 2025, titled "Press Release and presentation on the financials and operational performance of the Company for the quarter and half year ended Se
AI summary

Jubilant Ingrevia filed its press release and investor presentation on financials and operations for the quarter and half year ended September 30, 2025, ahead of an investor conference call on October 27, 2025.

Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said quarterly EBITDA grew 8% year-over-year and Profit After Tax rose 18%; on a half-yearly basis, EBITDA grew 18% and Profit After Tax rose 34%.

Management said Specialty Chemicals revenue grew in double digits year-over-year with margins above 25% in the quarter, and that Chemical Intermediates reported its highest quarterly sales in six quarters.

Management said Nutrition pricing was slightly lower due to competitive pressure, which affected margins, while volumes grew year-over-year.

Management expects continued growth in H2 FY26, starts serving a major CDMO order in early 2026, and has broken ground on a new facility in Gajraula, expected to be completed by late 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2025board outcome
Dividend / buy-back, Results
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board of Jubilant Ingrevia Limited approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, at a meeting held October 27, 2025 (1:30 p.m. to 3:50 p.m.).

The filing encloses the unaudited results and the Walker Chandiok & Co LLP limited review reports on them, which carry no modification of conclusion.

The standalone cash flow statement shows net cash generated from operating activities of Rs 8,069 lakhs... [see note]

Dividend paid in the half year was Rs 3,968 lakhs (standalone cash flow statement).

Documents are also available on the company's website.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025credit rating
Rating
Jubilant Ingrevia Limited has informed the Exchange about Credit Rating
AI summary

CRISIL Ratings Limited, by letter dated August 12, 2025, reaffirmed its 'Crisil A1+' rating on Rs. 600 crore of Commercial Papers of the company.

The intimation is made under Regulation 30 of the SEBI Listing Regulations, 2015.

The rating documents will be posted on the company's website, www.jubilantingrevia.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025presentation
Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Jubilant Ingrevia Limited filed an intimation under SEBI Regulation 30 that management will meet institutional investors in person on August 19 and 20, 2025 at Sofitel BKC, Mumbai, at the Equirus Annual India Conference 2025, listing 23 investors including Edelweiss AMC, Axis Mutual Fund and HDFC Mutual Fund.

The schedule may change due to exigencies on the part of investors, analysts or the company.

An August 2025 investor presentation was enclosed for the meetings, covering Q1 FY26 results.

Management (Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia) said EBITDA for the quarter rose 29% YoY and profit after tax rose 54% YoY, with specialty chemical businesses growing double digit YoY.

Management said it anticipates continued growth and improved performance for FY26 and is on track to deliver a big CDMO order in early 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025transcript
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q1 FY26 earnings conference call (held July 31, 2025) for the quarter ended June 30, 2025.

Chairman Shyam Bhartia said Specialty Chemicals grew in double digits year-on-year, EBITDA rose 29% year-on-year and profit after tax rose 54% year-on-year.

Management said it expects continued growth in FY26 and is on track to deliver the big CDMO order in early 2026.

CEO Deepak Jain said the Specialty and Nutrition portfolio contributes about 63% of total revenue and 90% of EBITDA; Lean 2.0 targets annualized savings above Rs 100+ crore in FY26.

Varun Gupta (CFO) said Specialty Chemicals revenue grew 11% year-on-year with a record EBITDA of Rs 130 crore and 27% margin.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025presentation
Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
AI summary

Intimation under Regulation 30 that management will meet institutional investors in person in a mix of one-on-one and group meetings on August 6 and 7, 2025 in Singapore, organized by Nuvama Institutional Equities as part of its Nuvama India Conference; 13 investors are listed, and the schedule may change.

Filing encloses the August 2025 investor presentation for the meetings.

Presentation (management message by Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia) says Q1 FY26 EBITDA rose 29% YoY and profit after tax rose 54% YoY, with specialty chemical businesses growing double digit YoY.

Management says the Chemical Intermediates business has started to recover marginally with QoQ growth, and anticipates continued growth and improved performance in FY26, with a big CDMO order on track for early 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025presentation
Capex, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Press Release and presentation on the financials and operational performance ofthe Company for the first quarter ended June 30, 2025"
AI summary

Jubilant Ingrevia Limited filed its Q1 FY26 (quarter ended June 30, 2025) press release and investor presentation on July 31, 2025.

Total revenue was Rs 1,038 crore (down 1% QoQ, up 1% YoY); EBITDA was Rs 153 crore (up 29% YoY); profit after tax was Rs 75 crore (up 54% YoY); basic and diluted EPS was Rs 4.7.

Management said Specialty Chemicals grew double digits YoY, Chemical Intermediates started a marginal recovery, and the CDMO opportunity pipeline doubled in size in recent months.

Management stated it expects continued growth and improved performance in FY26 and is on track to deliver a large CDMO order in early 2026.

Net debt at June 30, 2025 was Rs 700 crore, against Rs 658 crore at March 31, 2025; capex for the quarter was Rs 54 crore.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025board outcome
Results
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board meeting held July 31, 2025 approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, along with limited review reports from Walker Chandiok & Co LLP.

Standalone total income for Q1 FY26 (quarter ended June 30, 2025) was Rs 98,418 lakhs, against Rs 97,831 lakhs in the corresponding quarter last year.

Standalone net profit for the quarter was Rs 5,849 lakhs, against Rs 3,251 lakhs in the year-ago quarter; basic and diluted EPS were Rs 3.70 (not annualised).

The unaudited results will also be posted on the company's website, www.jubilantingrevia.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 May 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange about Transcript
AI summary

Jubilant Ingrevia filed the transcript of its Q4 and FY25 earnings conference call held on May 13, 2025, on audited standalone and consolidated results for the quarter and year ended March 31, 2025.

Management (Chairman Shyam Bhartia) said Q4 EBITDA margin reached 14.7% and PAT rose 153% year-on-year; the Board recommended a final dividend of Rs.2.5 per share (Rs.39.8 crore outflow), making FY25 total dividend Rs.5 per share (Rs.79.8 crore).

CFO Varun Gupta said Q4 revenue was Rs.1,051 crore (vs Rs.1,071 crore a year earlier), EBITDA Rs.155 crore (up 54% year-on-year), and net debt Rs.658 crore with net debt-to-EBITDA of 1.18 times.

Management said Rs.1,745 crore of the Rs.2,000 crore capex plan from FY22 has been invested, and plans Rs.600 crore of capex in FY26, funded mainly through internal accruals.

Management said about 10% of sales are to the US, with roughly 2.5% of global sales potentially affected by US tariffs, and expects sustained growth driven by Specialty Chemicals and Nutrition and Health Solutions.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 May 2025presentation
Capex, Dividend / buy-back, Guidance, Results
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Press Release and presentation on the financials and operational performance of the Company for the fourth quarter and the financial y
AI summary

Jubilant Ingrevia filed its Q4 and FY25 press release and investor presentation (May 13, 2025) ahead of an earnings call.

Q4 FY25 total revenue was Rs 1,051 crore (down 2% YoY), EBITDA Rs 155 crore (up 54% YoY) with 15% margin, and PAT Rs 74 crore (up 153% YoY).

FY25 total revenue was Rs 4,178 crore (up 1% YoY), EBITDA Rs 557 crore (up 22%), and PAT Rs 251 crore (up 37%).

The Board recommended a final dividend of Rs 2.50 per equity share (250%) for FY25, a cash outflow of Rs 39.8 crore; with the interim dividend of Rs 2.50, the FY25 total is Rs 5 per share, amounting to Rs 79.8 crore.

Management said the impact of US tariffs on sales is expected to be minimal, with about 2.5% of global sales potentially affected, and that Acetic Anhydride volumes remained weak due to low Paracetamol demand.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 May 2025dividend
Dividend / buy-back, Results
Jubilant Ingrevia Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of 2.5 per equity share.
AI summary

Board of Jubilant Ingrevia Limited, meeting held May 13, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified auditor opinion.

Board recommended a final dividend of 250% (Rs. 2.50 per equity share of Re. 1 each) for FY ended March 31, 2025, payable within 30 days of the AGM if approved by shareholders.

Record date for final dividend payment fixed as Friday, July 25, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in